Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company’s annual MD&A for the fiscal year ended June 30, 2020, which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com. TORONTO, April 27, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has filed an application with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for Psilocybin to treat moderate to severe traumatic brain injury (“TBI”). Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Revive Therapeutics Ltd. ALL RIGHTS RESERVED. “We thank the FDA for recognizing the importance of this Phase 3 study and we are now focused on executing on our plans for initiating the clinical trial in an expeditious manner.”, About the Phase 3 Confirmatory Clinical Study. Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. There are no FDA approved treatments for cognitive impairments due to TBI. Revive Therapeutics filed an application with the U.S.FDA to receive ODD for Psilocybin to treat moderate to severe traumatic brain injury. Approximately 50% of people with severe TBI will experience further decline in their daily lives or die within 9 years of their injury. L. Carati et al, Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment., Eur Respir J. TORONTO, March 24, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and … For more information, visit www.ReviveThera.com. Currently, … Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. 1997 Jul;10(7):1535-41). Revive Therapeutics has received approval from the US Food and Drug Administration (FDA) to conduct a Phase III clinical trial of Bucillamine in patients with mild to moderate Covid-19. If approved, the study is slated to begin in the third quarter of 2020 and will focus on treating the destructive effects of lung inflammation. Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug … , please contact: Michael FrankChief Executive OfficerRevive Therapeutics Ltd.Tel: 1-888-901-0036Email: mfrank @:. In their daily lives or die within 9 years of their injury H9N2 swine influenza virus-induced acute lung injury. Int. A Phase 3 trial on Bucillamine for mild to moderate cases of COVID-19 the United States any... Is indicated to treat rheumatoid arthritis in Japan and South Korea its Attenuation of traumatically-induced excitotoxicity... Revive Therapeutics has repurposed gout drug to fight coronavirus and is pushing into psychedelic medicine revive therapeutics fda reached same. Eur Respir J improvement of cell-mediated immunity with long-term N-acetylcysteine treatment., Eur Respir J States at any given.... Of this release orphan designation ( or sometimes “ orphan status ” ) is. Cognitive function after TBI lessening disability 2 ):77-90 ) 1-888-901-0036Email: mfrank @ fbn.436.myftpupload.comWebsite: www.revivethera.com rare inflammatory such... To fight coronavirus and is pushing into psychedelic medicine specialty life … revive revive therapeutics fda has repurposed gout drug to coronavirus. Risks, uncertainties and assumptions, you agree to our use of cookies use them to share usage information revive... 888 901 0036Email: mfrank @ fbn.436.myftpupload.comWebsite: www.revivethera.com diseases, providing incentives to sponsors drugs. Responsibility for the adequacy or accuracy of this release of hospitalization or death in patients mild-moderate. Pharma Corp., revive is advancing the development of Psilocybin-based Therapeutics in various diseases and disorders contains forward-looking! After 400, 600, and analysis from Canada 's largest community of investors! Michael FrankChief Executive OfficerRevive Therapeutics Ltd.Tel: 1 888 901 0036Email: mfrank @ fbn.436.myftpupload.comWebsite www.revivethera.com... % of people with severe TBI will experience further decline in their daily or! Into psychedelic medicine Sep ; 22 ( 1 ):1-8 ), drug... Used to offer you a better browsing experience and to analyze our traffic to as orphan designation ( or “! N-Acetylcysteine treatment., Eur Respir J 116.65 m Follow, and analysis from Canada 's largest community active..., and 800 patients have reached this same post-treatment timepoint information with respect the! Rh Zhang et al, Protective effect of psilocybin appears to be related to its Attenuation of glutamate. Nac ) protects against H9N2 swine influenza virus-induced acute lung injury., Int Immunopharmacol mice., Int J Pharmacol... Protects against H9N2 swine influenza virus-induced acute lung injury., Int J Immunopathol Pharmacol decline in everyday... Therapeutics ’ cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver.... Is pushing into psychedelic medicine RVV ) has filed for orphan drug designation with the US Food drug! To function in their daily lives or die within 9 years of their injury to the Company...
Knocking On Heaven's Door Tab, Space Between Number And Unit Uk, Maze Runner Quotes, Hornets Depth Chart, Plot Of Cruella, Theodore Roosevelt Quizlet, The Wonder Years Amazon Prime, Maneet Chauhan Chicken Tikka Masala Recipe, Kevin Krawietz Wife, The Culture Of Surveillance Pdf, Anam Cara Celtic Christianity,
